Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis

Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis

Hepatic fibrosis is a wound-healing response to various chronic stimuli, including viral hepatitis B or C infection. Activated myofibroblasts, predominantly derived from the hepatic stellate cells (HSCs), regulate the balance between matrix metalloproteinases and their tissue inhibitors to maintain...

Full description

Bibliographic Details
Main Authors:	Tung-Hung Su, Jia-Horng Kao, Chun-Jen Liu
Format:	Article
Language:	English
Published:	MDPI AG 2014-06-01
Series:	International Journal of Molecular Sciences
Subjects:	hepatitis B hepatitis C hepatocellular carcinoma myofibroblast hepatic stellate cells antiviral therapy nucleos(t)ide analogs interferon molecular target agent macrophage
Online Access:	http://www.mdpi.com/1422-0067/15/6/10578

Similar Items

Hepatitis B viral factors and treatment responses in chronic hepatitis B
by: Chih-Lin Lin, et al.
Published: (2013-06-01)

Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy
by: Chih-Lin Lin, et al.
Published: (2020-10-01)

A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis
by: Wei Wei, et al.
Published: (2015-08-01)

Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs
by: Ming-Chao Tsai, et al.
Published: (2017-07-01)

Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent
by: Jing‐Houng Wang, et al.
Published: (2019-11-01)

Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study
by: Li Y, et al.
Published: (2021-08-01)

Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis
by: Oliver Krenkel, et al.
Published: (2019-05-01)

Extra- and Intra-Cellular Mechanisms of Hepatic Stellate Cell Activation
by: Yufei Yan, et al.
Published: (2021-08-01)

The rtA181 Mutation Produces Similar Clinical and Cellular Characteristics in Patients infected with Hepatitis B Virus Genotypes B and C
by: Li Ping, et al.
Published: (2014-12-01)

Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2*
by: Hitoshi Ikeda, et al.
Published: (2009-03-01)

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice
by: Mingfan Geng, et al.
Published: (2017-09-01)

Prevention of Hepatitis B Vertical Transmission: Focus on Antenatal Antiviral Administration
by: Anandhara Indriani Khumaedi, et al.
Published: (2016-12-01)

Anti-viral therapy for chronic hepatitis B and cirrhosis: monotherapy or combination?
by: SHI Yiwen
Published: (2015-03-01)

Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review
by: Faydra I. Lieveld, et al.
Published: (2013-05-01)

Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy
by: Er-Mei Li, et al.
Published: (2021-08-01)

TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
by: Bedair Dewidar, et al.
Published: (2019-11-01)

ALT Flare Predicts Hepatocellular Carcinoma Among Antiviral Treated Patients With Chronic Hepatitis B: A Cross-Country Cohort Study
by: Yanan Du, et al.
Published: (2021-01-01)

The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.
by: Jun eXu, et al.
Published: (2014-07-01)

Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy
by: Huang M, et al.
Published: (2019-10-01)

The Forkhead box F1 transcription factor inhibits collagen deposition and accumulation of myofibroblasts during liver fibrosis
by: Hannah M. Flood, et al.
Published: (2019-02-01)

The Flavonoid Quercetin Ameliorates Liver Inflammation and Fibrosis by Regulating Hepatic Macrophages Activation and Polarization in Mice
by: Xi Li, et al.
Published: (2018-02-01)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01)

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs
by: Tao Li, et al.
Published: (2018-01-01)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
by: Camila V Pereira, et al.
Published: (2016-04-01)

External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy
by: Honglian Gui, et al.
Published: (2021-08-01)

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
by: Ioannis Varbobitis, et al.
Published: (2016-09-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

Novel Therapies in HBV Infection
by: Giuseppe Foti, et al.
Published: (2019-12-01)

Placental Growth Factor Contributes to Liver Inflammation, Angiogenesis, Fibrosis in Mice by Promoting Hepatic Macrophage Recruitment and Activation
by: Xi Li, et al.
Published: (2017-07-01)

A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B
by: Jialing Zhou, et al.
Published: (2016-07-01)

Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy
by: Tien-Ching Lin, et al.
Published: (2019-11-01)

The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
by: Mian Wang, et al.
Published: (2021-09-01)

Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy
by: Nai-Hsuan Chien, et al.
Published: (2017-12-01)

Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling
by: Pil Soo Sung, et al.
Published: (2018-09-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
by: Li Liu
Published: (2020-02-01)

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01)

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)

Evolving insights on metabolism, autophagy and epigenetics in liver myofibroblasts
by: Zeribe Chike Nwosu, et al.
Published: (2016-06-01)

Anti-fibrotic treatments for chronic liver diseases: The present and the future
by: Naoshi Odagiri, et al.
Published: (2021-07-01)